A therapeutic vaccine aimed at reducing the viral load of patients with Human Immunodeficiency Virus (HIV), is currently in phase one of a clinical trial, in which its safety is studied.
According to Yayri Caridad Prieto Correa, a researcher from the Center for Genetic Engineering and Biotechnology (CIGB) here said that the nine patients involved in the trial did not show any adverse effects or toxicity, which is the main objective of the phase.
After preclinical studies in laboratory animals, and tests in the small group of humans, it was shown that the immune response of the organism is enhanced thanks to the use of the vaccine, although Prieto Correa insisted on not creating false expectations.
She told the Cuban News Agency that this is a multi-year project, and will take time which will include testing phases with a greater number of seropositives in which large-scale and comprehensive efficacy will be tested to determine whether or not to continue with its use.
, is currently in phase one of a clinical trial, in which its safety is studied){kind=link}